Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
Heron Therapeutics (Nasdaq: HRTX) appointed Thomas Cusack to its Board of Directors effective October 27, 2025. His appointment was made pursuant to a Cooperation Agreement with Rubric Capital dated August 8, 2025. Cusack brings more than 20 years of experience in investment management and corporate finance, including service as a Managing Director at Starboard Value from 2011–2025, a fund cited with approximately $9 billion assets under management. His background includes roles in M&A at Barclays Capital and Lehman Brothers and a B.S. in Finance & Accounting from NYU Stern.
The company said the appointment will add governance and investment-management expertise to the board as Heron pursues its commercial-stage objectives.
Heron Therapeutics (Nasdaq: HRTX) ha nominato Thomas Cusack al suo Consiglio di Amministrazione con effetto dal 27 ottobre 2025. La nomina è stata effettuata ai sensi di un Accordo di Cooperazione con Rubric Capital datato 8 agosto 2025. Cusack porta oltre 20 anni di esperienza nella gestione degli investimenti e nella finanza aziendale, tra cui il ruolo di Managing Director presso Starboard Value dal 2011 al 2025, un fondo citato con circa 9 miliardi di dollari di assets under management. Il suo background include ruoli in M&A presso Barclays Capital e Lehman Brothers e una laurea triennale in Finanza e Contabilità presso NYU Stern. L'azienda ha affermato che la nomina apporterà competenze di governance e di gestione degli investimenti al consiglio mentre Heron persegue i suoi obiettivi a livello di fase commerciale.
La società ha dichiarato che l'elezione aggiungerà al consiglio competenze di governance e gestione degli investimenti mentre Heron persegue i propri obiettivi nell'ambito della fase commerciale.
Heron Therapeutics (Nasdaq: HRTX) nombró a Thomas Cusack para su Junta Directiva con efecto a partir del 27 de octubre de 2025. Su nombramiento se realizó conforme a un Acuerdo de Cooperación con Rubric Capital fechado el 8 de agosto de 2025. Cusack aporta más de 20 años de experiencia en gestión de inversiones y finanzas corporativas, incluyendo su servicio como Director General en Starboard Value desde 2011 hasta 2025, un fondo citado con aproximadamente 9 mil millones de dólares en activos bajo gestión. Su trayectoria incluye roles en Fusiones y Adquisiciones en Barclays Capital y Lehman Brothers y una Licenciatura en Finanzas y Contabilidad de NYU Stern. La empresa afirmó que la nominación añadirá experiencia en gobernanza y gestión de inversiones al consejo mientras Heron avanza hacia sus objetivos en la etapa comercial.
La compañía dijo que la designación añadirá al consejo experiencia en gobernanza y gestión de inversiones a medida que Heron persigue sus objetivos comerciales.
Heron Therapeutics (Nasdaq: HRTX)가 2025년 10월 27일부로 이사회에 토마스 커삭(Thomas Cusack)을 임명했습니다. 이번 임명은 2025년 8월 8일자로 체결된 Rubric Capital과의 협력 계약에 따라 이루어졌습니다. Cusack은 투자 관리 및 기업 재무 분야에서 20년 이상의 경력을 보유하고 있으며, 2011년부터 2025년까지 Starboard Value의 상무 이사로 재직했고 이 펀드는 약 90억 달러의 자산을 운용하는 것으로 알려져 있습니다. 그의 경력에는 Barclays Capital과 Lehman Brothers의 M&A 역할과 NYU Stern의 재무 및 회계 학사가 포함됩니다. 회사는 이사회에 거버넌스 및 투자 관리 전문 지식을 더해 Heron이 상용화 단계의 목표를 추구하는 데 도움이 될 것이라고 밝혔습니다.
회사는 또한 임명이 이사회에 거버넌스와 투자 관리에 대한 전문 지식을 추가한다고 밝혔습니다.
Heron Therapeutics (Nasdaq : HRTX) a nommé Thomas Cusack au conseils d'administration à compter du 27 octobre 2025. Sa nomination a été effectuée en vertu d'un accord de coopération avec Rubric Capital daté du 8 août 2025. Cusack apporte plus de 20 ans d'expérience en gestion d'investissements et en finance d'entreprise, notamment en tant que Managing Director chez Starboard Value de 2011 à 2025, un fonds cité pour environ 9 milliards de dollars d'actifs sous gestion. Son parcours comprend des rôles dans les fusions et acquisitions chez Barclays Capital et Lehman Brothers et une licence B.S. en Finance et Comptabilité obtenue à NYU Stern. La société a indiqué que la nomination apporterait au conseil des compétences en gouvernance et en gestion des investissements alors que Heron poursuit ses objectifs au stade commercial.
La société a ajouté que cette nomination apportera une expertise en gouvernance et en gestion des investissements au conseil pendant que Heron continue à viser ses objectifs dans le cadre de la phase commerciale.
Heron Therapeutics (Nasdaq: HRTX) hat Thomas Cusack zum Mitglied des Vorstands ernannt, mit Wirkung zum 27. Oktober 2025. Die Ernennung erfolgte gemäß einer Kooperationsvereinbarung mit Rubric Capital vom 8. August 2025. Cusack bringt mehr als 20 Jahre Erfahrung im Investment-Management und in der Unternehmensfinanzierung mit, darunter seine Tätigkeit als Managing Director bei Starboard Value von 2011 bis 2025, ein Fonds, der mit ca. 9 Milliarden USD Vermögenswerte verwaltet wird. Sein Hintergrund umfasst Rollen im M&A bei Barclays Capital und Lehman Brothers und einen B.S. in Finance & Accounting von der NYU Stern. Das Unternehmen sagte, die Ernennung werde dem Vorstand Governance- und Investment-Management-Expertise hinzufügen, während Heron seine kommerziellen Ziele weiterverfolgt.
Das Unternehmen erklärte, dass die Ernennung dem Vorstand zusätzliche Governance- und Investitionsmanagement-Kompetenz bringen werde, während Heron seine kommerziellen Ziele verfolgt.
Heron Therapeutics (Nasdaq: HRTX) عينت توماس كوزاك في مجلس إدارتها اعتبارًا من 27 أكتوبر 2025. تم التعيين وفقًا لـ اتفاقية تعاون مع Rubric Capital مؤرخة في 8 أغسطس 2025. يجلب كوزاك أكثر من 20 عامًا من الخبرة في إدارة الاستثمارات والتمويل المؤسسي، بما في ذلك عمله كـ Managing Director في Starboard Value من 2011 إلى 2025، وهو صندوق يذكر أن أصوله تبلغ نحو 9 مليارات دولار تحت الإدارة. تشمل خلفيته أدوارًا في الاندماج والاستحواذ (M&A) في Barclays Capital وLehman Brothers، وشهادة B.S. في المالية والمحاسبة من NYU Stern. قالت الشركة إن التعيين سيضيف إلى المجلس خبرة في الحوكمة وإدارة الاستثمارات بينما تسعى Heron لتحقيق أهدافها في مرحلة التسويق التجاري.
وقالت الشركة إن التعيين سيضيف إلى المجلس خبرة في الحوكمة وإدارة الاستثمارات بينما تواصل Heron سعيها لتحقيق أهدافها في مرحلة العمل التجاري.
- Director with 20+ years of investment management experience
- Starboard background: served 2011–2025 at a fund with ~$9 billion AUM
- Appointment effective October 27, 2025 under a formal cooperation agreement
- Appointment arose from a Cooperation Agreement with Rubric Capital dated August 8, 2025
CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cusack has extensive experience in matters related to corporate finance, investment management, and corporate governance. Mr. Cusack was appointed to the Board pursuant to the Cooperation Agreement entered into between the Company and Rubric Capital Management LP, dated as of August 8, 2025.
Mr. Cusack was appointed as a director of Heron as of October 27, 2025. Mr. Cusack has more than 20 years of experience in investment management and corporate finance. Most recently, from 2011 to 2025, he served as a Managing Director of Starboard Value LP, a New York-based investment fund with approximately
“We are pleased to welcome Tom to Heron’s Board of Directors,” said Craig Collard, Chief Executive Officer of Heron. “Tom will undoubtedly bring a wealth of perspective to benefit our efforts to build momentum at Heron.”
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.
Forward-looking Statements
This news release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
Investor Relations and Media Contact:
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
iduarte@herontx.com
858-251-4400
FAQ
Who is Thomas Cusack and when was he appointed to Heron Therapeutics (HRTX) board?
Why was Thomas Cusack added to Heron Therapeutics (HRTX) board on October 27, 2025?
What experience does new Heron (HRTX) director Thomas Cusack bring from Starboard Value?
Does Thomas Cusack have M&A experience relevant to Heron (HRTX)?
How might the October 27, 2025 board appointment affect Heron Therapeutics (HRTX) governance?
